Anti-Human CD11a (Efalizumab)

Pricing & Details

Product No.LT800
Clone
hu1124
Protein
CD11a
Formats AvailableView All
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
ITGAL; integrin alpha L; LFA-1; LFA1A
Isotype
Human IgG1κ
Applications
B
,
CyTOF®
,
ELISA
,
FA
,
FC
,
IHC
Prod No.
Size
Price
Avail.
Qty
Add to cart
LT800-Custom
Custom
In stock
Max:
Min: 1
Step: 1
LT800-1.0 mg
1.0 mg
$175.00
In stock
Max:
Min: 1
Step: 1
LT800-5.0 mg
5.0 mg
$650.00
In stock
Max:
Min: 1
Step: 1
LT800-25 mg
25 mg
$2,450.00
In stock
Max:
Min: 1
Step: 1
LT800-50 mg
50 mg
$3,750.00
In stock
Max:
Min: 1
Step: 1
LT800-100 mg
100 mg
$5,100.00
In stock
Max:
Min: 1
Step: 1

Antibody Details

Product Details

Reactivity Species
Human
Host Species
Human
Expression Host
HEK-293
FC Effector Activity
Active
Immunogen
Human CD11a
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Efalizumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Other Applications Reported In Literature ?
FA
B
CyTOF®
ELISA
IHC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Efalizumab. Clone hu1124 recognizes human CD11a. This product is for research use only.
Antigen Distribution
CD11a is expressed on all leukocytes.
Background
CD11a and CD18 are the Integrin alpha-L and beta-2 subunits that combine to form LFA-1, a glycoprotein and a member of the Integrin family. The Integrin alpha-L/beta-2 complex is a receptor for ICAM1, ICAM2, ICAM3, ICAM4 and F11R. LFA-1 participates in the immunological synapses between CD8+ T lymphocytes and antigen-presenting cells. Efalizumab binds to the CD11a subunit of LFA-1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Anti-Human CD11a (Efalizumab) utilizes the same variable regions from the therapeutic antibody Efalizumab making it ideal for research projects.

Antigen Details

Protein
PubMed
NCBI Gene Bank ID
Research Area
Cell Adhesion
.
Cell Biology
.
Costimulatory Molecules
.
Immunology
.
Innate Immunity
.
Neuroinflammation
.
Neuroscience

References & Citations

1. Gottlieb, AB. et al. (2002) Arch Dermatol. 138(5):591-600.
Elisa Sandwich Protocol
Flow Cytometry
IHC

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Cookie Policy
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy.